A
A. J. Yates
Researcher at Merck & Co.
Publications - 20
Citations - 3284
A. J. Yates is an academic researcher from Merck & Co.. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 16, co-authored 20 publications receiving 3212 citations. Previous affiliations of A. J. Yates include Creighton University & University of Alberta.
Papers
More filters
Journal ArticleDOI
Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study
H. A. P. Pols,Dieter Felsenberg,David A. Hanley,Jan J. Stepan,M. Muñoz-Torres,T. J. Wilkin,G. Qin-sheng,A. M. Galich,K. Vandormael,A. J. Yates,B. Stych +10 more
TL;DR: For postmenopausal women with low bone mass, alendronate is well tolerated and produces significant, progressive increases in BMD at the lumbar spine and hip in addition to significant reduction in the risk of nonvertebral fracture.
Journal ArticleDOI
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,R. D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.
Journal ArticleDOI
Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women
Pernille Ravn,Giovanni Cizza,Nina H. Bjarnason,Desmond E. Thompson,M. Daley,R. D. Wasnich,Michael R. McClung,David J. Hosking,A. J. Yates,C. Christiansen +9 more
TL;DR: Thinness is an important risk factor for low bone mass and increased bone loss in postmenopausal women and because the response to alendronate treatment is independent of fat mass parameters, prevention of post menopausal osteoporosis can be equally achieved in thinner and heavier women.
Journal ArticleDOI
Prevention of Bone Loss With Alendronate in Postmenopausal Women Under 60 Years of Age
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,Richard D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen-progestin and was well tolerated, with a safety profile similar to that of placebo or estrogen- Progestin.
Journal ArticleDOI
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
Michael R. McClung,B Clemmesen,Daifotis Anastasia G,N L Gilchrist,John A. Eisman,Robert S. Weinstein,Fuleihan G el-H,C Reda,A. J. Yates,Pernille Ravn +9 more
TL;DR: A 3-year randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy of alendronate therapy in preventing bone loss in healthy women who had recently experienced menopause.